Uses of Uplizna

This is an automatically translated article.

Uplizna drug has the main ingredient Inebilizumab-cdon, which is commonly used in the treatment of cases of neuromyelitis optica or neuromyelitis optica spectrum disorders (NMOSD). A copy of the ingredients, uses, doses and side effects of Uplizna will give patients the best treatment results.

1. What is Uplizna?

Uplizna drug is prepared in the form of a 10 ml solution vial, with the main ingredients including:
Active ingredients: Inebilizumab-cdon 100mg in 10 ml of solution. Excipients: L-histidine, L-histidine hydrochloride monohydrate, Polysorbate 80, Sodium chloride, α-Trehalose dihydrate and Water for injection just enough for 1 vial of 10 ml. The exact mechanism by which inebilizumab-cdon acts on the treatment of neuroinflammatory optica spectrum disorder (NMOSD) is unknown. Several scientific studies have suggested that inebilizumab-cdon is involved in binding to CD19, specifically a cytolytic antibody directed towards CD19 (cell surface antigen present on mature B lymphocytes). and pre-B lymphocytes). After cell surface binding to B lymphocytes, Inebilizumab-cdon induces antibody-dependent cytolysis.

2. What are the effects of Uplizna?

Uplizna (inebilizumab-cdon) is used to treat neuroinflammatory optica spectrum disorder (NMOSD) in adult patients who are positive for anti-Aquaporin-4 (AQP4) antibodies.

3. Contraindications of Uplizna

Hypersensitivity to any of the ingredients of Uplizna. History of allergy to other medicines containing Inebilizumab-cdon. Patients with active hepatitis B infection. Tuberculosis is active or untreated.

4. Dosage and how to use Uplizna

4.1. Dosage: Initial dose: 300 mg intravenous infusion / time, 2 weeks after the second intravenous infusion of 300 mg. Next dose (after 6 months from the first infusion): 300 mg IV every 6 months. 4.2. How to use Mix 3 vials of Uplizna 10 ml into 250 ml of 0.9% NaCl solution. Gently stir the diluted solution. Administer the solution intravenously using an electric syringe, gradually increasing the infusion rate to complete after 90 minutes, according to the instructions in the following table:
Closely monitor the patient during the infusion and for at least one hour after the infusion is completed.

5. Notes when using Uplizna

Treatment with Uplizna in high doses or for a long time can cause side effects such as:
Infusion reactions: Headache, nausea, drowsiness, shortness of breath, fever, muscle pain, rash or other side effects. other signs or symptoms. Infections: Urinary tract infections, nasopharyngitis, upper respiratory tract infections, and influenza. Immune Globulin Reduction: Decreased levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM). Other: Joint pain, back pain, headache, neutropenia, decreased lymphocyte count. Uplizna should be discontinued when detecting the above symptoms or any other unusual symptoms and promptly notify the medical staff for timely treatment.
Note the use of Uplizna drug in the following subjects:
Caution when using Uplizna drug for children, adults over 65 years old, patients with a history of or being infected with Hepatitis B Virus, bacterial infection, infection virus on the brain, patients with tuberculosis, injected with any vaccine within less than 4 weeks, reduced immune globulin, severe liver and kidney function impairment. Pregnancy: Uplizna is an IgG1 monoclonal antibody that can cross the placental barrier. There are no adequate data on the risk associated with the use of Uplizna in pregnant women. However, transient peripheral B-cell depletion and leukopenia have been reported in infants born to mothers receiving Uplizna during pregnancy. Therefore, the drug Uplizna should only be used in this population when the benefits outweigh the possible harms. Lactation: There are no data on the presence of the active ingredient ineblizumab-cdon in breast milk, effects on the nursing infant or on milk production. However, the infant health and developmental benefits must be considered together with the mother's clinical need for Uplizna.

6. Uplizna drug interactions

Interactions with other drugs:
Using Uplizna with immunosuppressive drugs such as systemic corticosteroids, antihistamines and antipyretics may increase the risk of infection and other effects of Uplizna. Below is the time to perform Uplizna infusion in case it is mandatory to use it in combination with the above drugs:
Above is an overview of ingredients, uses, indications, contraindications and notes when using Uplizna. In order to bring the best treatment results for themselves and their families, patients should carefully read the instructions for use of Uplizna medicine and strictly follow the instructions of the treating doctor.